 Eva Nozik
Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Superoxide Dismutase | 18 | 2023 | 305 | 4.050 |
Why?
| | Acute Lung Injury | 8 | 2023 | 268 | 2.650 |
Why?
| | Hypertension, Pulmonary | 20 | 2022 | 1736 | 2.200 |
Why?
| | Lung | 25 | 2023 | 3521 | 1.540 |
Why?
| | Vascular Remodeling | 6 | 2021 | 153 | 1.430 |
Why?
| | Bleomycin | 8 | 2018 | 228 | 1.280 |
Why?
| | Pneumonia | 5 | 2022 | 563 | 1.170 |
Why?
| | Pulmonary Artery | 13 | 2021 | 1024 | 1.150 |
Why?
| | Hypoxia | 7 | 2022 | 956 | 1.110 |
Why?
| | Mice, Inbred C57BL | 14 | 2023 | 4681 | 1.090 |
Why?
| | Hypertrophy, Right Ventricular | 8 | 2022 | 141 | 1.030 |
Why?
| | Oxidation-Reduction | 6 | 2023 | 917 | 1.000 |
Why?
| | Lung Injury | 5 | 2021 | 192 | 0.950 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2022 | 333 | 0.930 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2023 | 14 | 0.840 |
Why?
| | Animals | 52 | 2023 | 31567 | 0.820 |
Why?
| | Superoxides | 1 | 2023 | 190 | 0.810 |
Why?
| | Disease Models, Animal | 10 | 2023 | 3498 | 0.770 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2018 | 1880 | 0.770 |
Why?
| | Mice | 29 | 2023 | 14845 | 0.750 |
Why?
| | Reactive Oxygen Species | 8 | 2023 | 522 | 0.750 |
Why?
| | Macrophages, Alveolar | 5 | 2023 | 348 | 0.730 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2017 | 27 | 0.720 |
Why?
| | Hyaluronic Acid | 2 | 2022 | 189 | 0.700 |
Why?
| | Platelet Activation | 1 | 2020 | 65 | 0.700 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 192 | 0.700 |
Why?
| | Myocytes, Smooth Muscle | 6 | 2022 | 236 | 0.700 |
Why?
| | Pulmonary Fibrosis | 4 | 2017 | 321 | 0.680 |
Why?
| | Endothelium, Vascular | 4 | 2018 | 830 | 0.660 |
Why?
| | Receptor, EphA2 | 2 | 2018 | 19 | 0.650 |
Why?
| | Alpha-Globulins | 2 | 2018 | 20 | 0.620 |
Why?
| | Inflammation | 8 | 2023 | 2464 | 0.620 |
Why?
| | Blood Platelets | 1 | 2020 | 326 | 0.590 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 19 | 0.590 |
Why?
| | Liposomes | 3 | 2017 | 146 | 0.590 |
Why?
| | Protective Agents | 1 | 2018 | 37 | 0.580 |
Why?
| | Endothelial Cells | 4 | 2015 | 677 | 0.570 |
Why?
| | MicroRNAs | 2 | 2022 | 600 | 0.530 |
Why?
| | Early Growth Response Protein 1 | 2 | 2011 | 24 | 0.480 |
Why?
| | Vasodilator Agents | 6 | 2017 | 302 | 0.460 |
Why?
| | Pulmonary Alveoli | 2 | 2021 | 372 | 0.450 |
Why?
| | Mitochondria | 1 | 2019 | 744 | 0.440 |
Why?
| | Peptides | 2 | 2018 | 847 | 0.430 |
Why?
| | Extracellular Space | 2 | 2011 | 116 | 0.430 |
Why?
| | Hemoglobins | 4 | 2017 | 308 | 0.400 |
Why?
| | Mice, Knockout | 6 | 2023 | 2563 | 0.400 |
Why?
| | Metalloporphyrins | 1 | 2013 | 103 | 0.400 |
Why?
| | Xanthine Oxidase | 1 | 2011 | 71 | 0.380 |
Why?
| | Animals, Newborn | 5 | 2022 | 777 | 0.380 |
Why?
| | Inflammasomes | 1 | 2013 | 115 | 0.380 |
Why?
| | Cell Proliferation | 8 | 2022 | 2173 | 0.360 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 157 | 0.360 |
Why?
| | Lipopolysaccharides | 4 | 2023 | 813 | 0.360 |
Why?
| | Signal Transduction | 6 | 2019 | 4501 | 0.360 |
Why?
| | Up-Regulation | 2 | 2013 | 802 | 0.330 |
Why?
| | Carrier Proteins | 1 | 2013 | 694 | 0.310 |
Why?
| | Trachea | 1 | 2010 | 223 | 0.310 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 613 | 0.290 |
Why?
| | Sildenafil Citrate | 2 | 2018 | 57 | 0.290 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2018 | 110 | 0.290 |
Why?
| | Rats, Sprague-Dawley | 10 | 2018 | 2182 | 0.280 |
Why?
| | Male | 23 | 2023 | 55400 | 0.270 |
Why?
| | Mice, Transgenic | 6 | 2022 | 1947 | 0.270 |
Why?
| | Nanoparticles | 2 | 2021 | 312 | 0.270 |
Why?
| | Electron Spin Resonance Spectroscopy | 2 | 2023 | 86 | 0.260 |
Why?
| | Cells, Cultured | 6 | 2021 | 3861 | 0.250 |
Why?
| | Rats | 11 | 2018 | 4913 | 0.250 |
Why?
| | Gene Expression Regulation | 5 | 2018 | 2322 | 0.240 |
Why?
| | Myofibroblasts | 3 | 2022 | 115 | 0.230 |
Why?
| | Humans | 33 | 2023 | 114050 | 0.230 |
Why?
| | Hydroxylamine | 1 | 2023 | 8 | 0.220 |
Why?
| | Nitric Oxide | 4 | 2018 | 817 | 0.220 |
Why?
| | Interleukin-1beta | 2 | 2018 | 368 | 0.220 |
Why?
| | NF-kappa B | 3 | 2018 | 636 | 0.210 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2018 | 191 | 0.210 |
Why?
| | Uncoupling Protein 2 | 1 | 2022 | 8 | 0.200 |
Why?
| | Hyaluronan Synthases | 1 | 2022 | 1 | 0.200 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2023 | 49 | 0.200 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2015 | 181 | 0.200 |
Why?
| | Oxidative Stress | 4 | 2022 | 1068 | 0.190 |
Why?
| | Adventitia | 2 | 2012 | 37 | 0.190 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2021 | 10 | 0.190 |
Why?
| | Succinate Dehydrogenase | 1 | 2021 | 42 | 0.180 |
Why?
| | Alveolar Epithelial Cells | 2 | 2023 | 93 | 0.180 |
Why?
| | Platelet Factor 4 | 1 | 2020 | 21 | 0.180 |
Why?
| | Chemokine CCL5 | 1 | 2020 | 43 | 0.180 |
Why?
| | Cell Membrane Permeability | 2 | 2018 | 83 | 0.180 |
Why?
| | Lung Diseases | 3 | 2017 | 690 | 0.180 |
Why?
| | Hemodynamics | 4 | 2018 | 1015 | 0.170 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 140 | 0.170 |
Why?
| | Reperfusion Injury | 1 | 2022 | 252 | 0.160 |
Why?
| | Staphylococcus aureus | 1 | 2023 | 385 | 0.160 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2017 | 580 | 0.160 |
Why?
| | Advisory Committees | 1 | 2020 | 207 | 0.160 |
Why?
| | Chronic Disease | 2 | 2017 | 1578 | 0.160 |
Why?
| | Ephrin-A2 | 1 | 2018 | 3 | 0.160 |
Why?
| | Glioma | 1 | 2022 | 285 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2020 | 177 | 0.160 |
Why?
| | Heparitin Sulfate | 1 | 2018 | 39 | 0.150 |
Why?
| | Glycocalyx | 1 | 2018 | 18 | 0.150 |
Why?
| | Drug Repositioning | 1 | 2018 | 13 | 0.150 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2018 | 88 | 0.150 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 28 | 0.150 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.150 |
Why?
| | Mucociliary Clearance | 1 | 2018 | 42 | 0.150 |
Why?
| | Ventricular Pressure | 2 | 2015 | 39 | 0.150 |
Why?
| | Blood Pressure | 5 | 2022 | 1531 | 0.150 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 30 | 0.150 |
Why?
| | Physical Exertion | 1 | 2018 | 209 | 0.140 |
Why?
| | Energy Metabolism | 1 | 2022 | 727 | 0.140 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 30 | 0.140 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2017 | 36 | 0.140 |
Why?
| | PPAR gamma | 1 | 2018 | 182 | 0.140 |
Why?
| | Arginine | 2 | 2014 | 236 | 0.140 |
Why?
| | Kidney | 2 | 2022 | 1182 | 0.140 |
Why?
| | Caspase 1 | 2 | 2018 | 140 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 453 | 0.130 |
Why?
| | Disease Progression | 3 | 2019 | 2371 | 0.130 |
Why?
| | rho-Associated Kinases | 2 | 2017 | 80 | 0.130 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 500 | 0.130 |
Why?
| | Heart Ventricles | 1 | 2021 | 723 | 0.130 |
Why?
| | Ventricular Function, Right | 2 | 2015 | 256 | 0.130 |
Why?
| | MAP Kinase Signaling System | 2 | 2021 | 271 | 0.130 |
Why?
| | Muscle, Smooth, Vascular | 4 | 2021 | 409 | 0.130 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1144 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 637 | 0.120 |
Why?
| | Anemia, Sickle Cell | 1 | 2018 | 215 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 86 | 0.120 |
Why?
| | Cholestasis | 1 | 2018 | 225 | 0.120 |
Why?
| | Administration, Inhalation | 4 | 2018 | 637 | 0.120 |
Why?
| | Haptoglobins | 1 | 2015 | 47 | 0.120 |
Why?
| | Pericytes | 1 | 2014 | 24 | 0.120 |
Why?
| | Altitude | 1 | 2018 | 435 | 0.120 |
Why?
| | Hyperoxia | 1 | 1995 | 99 | 0.110 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2014 | 122 | 0.110 |
Why?
| | Macrophages | 2 | 2018 | 1259 | 0.110 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 534 | 0.110 |
Why?
| | Vascular Diseases | 2 | 2015 | 233 | 0.110 |
Why?
| | Alprostadil | 1 | 2013 | 31 | 0.110 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 90 | 0.100 |
Why?
| | Apoptosis | 4 | 2022 | 2349 | 0.100 |
Why?
| | Transcriptome | 1 | 2018 | 723 | 0.100 |
Why?
| | I-kappa B Kinase | 1 | 2013 | 50 | 0.100 |
Why?
| | Protein Binding | 1 | 2018 | 1888 | 0.100 |
Why?
| | Lactic Acid | 3 | 2023 | 272 | 0.100 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2013 | 71 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 496 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2015 | 221 | 0.100 |
Why?
| | I-kappa B Proteins | 1 | 2013 | 80 | 0.100 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2015 | 184 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1518 | 0.100 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2013 | 144 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2014 | 385 | 0.090 |
Why?
| | Altitude Sickness | 1 | 2013 | 170 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 1875 | 0.090 |
Why?
| | Interleukin-18 | 1 | 2013 | 217 | 0.090 |
Why?
| | Catalase | 4 | 2015 | 118 | 0.090 |
Why?
| | Vasoconstrictor Agents | 2 | 2022 | 113 | 0.090 |
Why?
| | Transcriptional Activation | 1 | 2013 | 337 | 0.090 |
Why?
| | Phosphorylation | 1 | 2015 | 1558 | 0.090 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2011 | 48 | 0.090 |
Why?
| | Drug Carriers | 3 | 2018 | 112 | 0.090 |
Why?
| | Blood Vessels | 1 | 2012 | 179 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2018 | 2764 | 0.090 |
Why?
| | Stress, Physiological | 2 | 2012 | 379 | 0.090 |
Why?
| | Rats, Inbred WKY | 1 | 2010 | 32 | 0.090 |
Why?
| | Microvessels | 1 | 2011 | 66 | 0.090 |
Why?
| | Blood Circulation | 1 | 2010 | 36 | 0.090 |
Why?
| | Drug Administration Routes | 1 | 2010 | 38 | 0.090 |
Why?
| | Airway Remodeling | 1 | 2011 | 57 | 0.090 |
Why?
| | Accreditation | 1 | 2011 | 76 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1011 | 0.090 |
Why?
| | Nitrosation | 1 | 2010 | 8 | 0.090 |
Why?
| | Liver | 1 | 2018 | 1633 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2090 | 0.090 |
Why?
| | Phenotype | 2 | 2015 | 2784 | 0.090 |
Why?
| | Models, Biological | 1 | 2017 | 1611 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2013 | 475 | 0.080 |
Why?
| | Workload | 1 | 2011 | 131 | 0.080 |
Why?
| | Female | 7 | 2022 | 59328 | 0.080 |
Why?
| | Tyrosine | 1 | 2010 | 210 | 0.080 |
Why?
| | Vasoconstriction | 1 | 2010 | 177 | 0.080 |
Why?
| | Cattle | 1 | 2011 | 918 | 0.080 |
Why?
| | Fetus | 1 | 2013 | 698 | 0.080 |
Why?
| | Time Factors | 1 | 2018 | 6077 | 0.070 |
Why?
| | Gene Expression | 1 | 2013 | 1417 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2010 | 445 | 0.070 |
Why?
| | Fibroblasts | 3 | 2022 | 834 | 0.070 |
Why?
| | Porosity | 2 | 2018 | 88 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 784 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2022 | 250 | 0.070 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 366 | 0.070 |
Why?
| | Critical Care | 1 | 2011 | 472 | 0.070 |
Why?
| | Sheep | 2 | 2022 | 761 | 0.070 |
Why?
| | Antioxidants | 3 | 2014 | 529 | 0.060 |
Why?
| | Sulfonamides | 2 | 2022 | 444 | 0.060 |
Why?
| | Polyglycolic Acid | 2 | 2017 | 43 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2010 | 946 | 0.060 |
Why?
| | Lipid Peroxidation | 2 | 2017 | 139 | 0.060 |
Why?
| | Cell Line | 3 | 2015 | 2629 | 0.060 |
Why?
| | Vascular Resistance | 2 | 2015 | 340 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1735 | 0.050 |
Why?
| | Nitrogen Oxides | 1 | 2023 | 47 | 0.050 |
Why?
| | Pediatrics | 1 | 2011 | 982 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2015 | 147 | 0.050 |
Why?
| | Phosphofructokinase-2 | 1 | 2022 | 14 | 0.050 |
Why?
| | Breath Tests | 1 | 2023 | 82 | 0.050 |
Why?
| | Spectrum Analysis | 1 | 2023 | 83 | 0.050 |
Why?
| | Lasers | 1 | 2023 | 121 | 0.050 |
Why?
| | Tryptophan Hydroxylase | 1 | 2022 | 52 | 0.050 |
Why?
| | Hydrogen Peroxide | 2 | 2012 | 288 | 0.050 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 71 | 0.050 |
Why?
| | Cerium | 1 | 2021 | 13 | 0.050 |
Why?
| | 3' Untranslated Regions | 1 | 2022 | 129 | 0.050 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2022 | 100 | 0.050 |
Why?
| | Internship and Residency | 1 | 2011 | 920 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 211 | 0.050 |
Why?
| | Angiotensin II | 1 | 2021 | 87 | 0.050 |
Why?
| | Mutation | 1 | 2011 | 3338 | 0.050 |
Why?
| | Diet, High-Fat | 1 | 2022 | 225 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 172 | 0.040 |
Why?
| | Serotonin | 1 | 2022 | 292 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2021 | 146 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2023 | 445 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 452 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 76 | 0.040 |
Why?
| | Syndecans | 1 | 2018 | 5 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 1690 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2022 | 605 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 315 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 185 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2018 | 60 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 246 | 0.040 |
Why?
| | Caspases, Initiator | 1 | 2018 | 18 | 0.040 |
Why?
| | Amino Acid Oxidoreductases | 2 | 1995 | 18 | 0.040 |
Why?
| | Liver X Receptors | 1 | 2018 | 30 | 0.040 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2018 | 34 | 0.040 |
Why?
| | Endothelins | 1 | 2018 | 61 | 0.040 |
Why?
| | Drug Liberation | 1 | 2018 | 25 | 0.040 |
Why?
| | Capillary Permeability | 1 | 2018 | 137 | 0.040 |
Why?
| | Genotype | 2 | 2014 | 1757 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1360 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 89 | 0.040 |
Why?
| | Stem Cells | 2 | 2012 | 541 | 0.040 |
Why?
| | Hemolysis | 1 | 2018 | 143 | 0.040 |
Why?
| | Histones | 1 | 2022 | 529 | 0.040 |
Why?
| | Critical Illness | 1 | 2022 | 640 | 0.040 |
Why?
| | Nitric Oxide Synthase | 2 | 1995 | 209 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 899 | 0.040 |
Why?
| | Monocrotaline | 1 | 2017 | 26 | 0.040 |
Why?
| | Lipoproteins | 1 | 2018 | 159 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 18 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 96 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 228 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 147 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 850 | 0.030 |
Why?
| | Polyethyleneimine | 1 | 2017 | 18 | 0.030 |
Why?
| | Hepatocytes | 1 | 2018 | 195 | 0.030 |
Why?
| | Caspases | 1 | 2018 | 243 | 0.030 |
Why?
| | Rabbits | 2 | 1995 | 733 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2017 | 98 | 0.030 |
Why?
| | Microspheres | 1 | 2017 | 123 | 0.030 |
Why?
| | Sex Factors | 1 | 2022 | 1707 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 192 | 0.030 |
Why?
| | Placenta | 1 | 2022 | 628 | 0.030 |
Why?
| | Models, Animal | 1 | 2018 | 340 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 99 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 820 | 0.030 |
Why?
| | Cytokines | 1 | 2023 | 1824 | 0.030 |
Why?
| | Particle Size | 1 | 2017 | 317 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 949 | 0.030 |
Why?
| | Surface Properties | 1 | 2017 | 385 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2022 | 2700 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 1995 | 38 | 0.030 |
Why?
| | Free Radicals | 1 | 1995 | 99 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1995 | 109 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 725 | 0.030 |
Why?
| | Sepharose | 1 | 2014 | 31 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 198 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3003 | 0.030 |
Why?
| | Platelet Activating Factor | 1 | 1994 | 69 | 0.030 |
Why?
| | Infant, Premature | 1 | 2017 | 478 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 153 | 0.030 |
Why?
| | Glycine | 1 | 2014 | 152 | 0.030 |
Why?
| | Iron | 1 | 2015 | 232 | 0.030 |
Why?
| | Permeability | 1 | 2013 | 149 | 0.030 |
Why?
| | Endothelin-1 | 1 | 2015 | 168 | 0.030 |
Why?
| | Quality Improvement | 1 | 2020 | 944 | 0.030 |
Why?
| | 1,2-Dipalmitoylphosphatidylcholine | 1 | 2013 | 10 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2013 | 52 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2017 | 673 | 0.030 |
Why?
| | Heparin | 1 | 2014 | 225 | 0.030 |
Why?
| | von Willebrand Factor | 1 | 2013 | 55 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2013 | 56 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 107 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 4883 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 118 | 0.030 |
Why?
| | Drug Stability | 1 | 2013 | 151 | 0.030 |
Why?
| | Vasa Vasorum | 1 | 2012 | 33 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1311 | 0.030 |
Why?
| | Cyclic N-Oxides | 1 | 2012 | 30 | 0.030 |
Why?
| | Infusion Pumps | 1 | 2012 | 31 | 0.030 |
Why?
| | Biomarkers | 1 | 2022 | 3397 | 0.030 |
Why?
| | Spin Labels | 1 | 2012 | 44 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 158 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2013 | 142 | 0.020 |
Why?
| | Aerosols | 1 | 2013 | 150 | 0.020 |
Why?
| | Cardiac Output | 1 | 2012 | 143 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 225 | 0.020 |
Why?
| | Receptor, TIE-2 | 1 | 2011 | 12 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 722 | 0.020 |
Why?
| | Cerebellum | 1 | 2013 | 199 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6195 | 0.020 |
Why?
| | Cholesterol | 1 | 2013 | 368 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4090 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 285 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 5499 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2011 | 132 | 0.020 |
Why?
| | Oxygen | 1 | 1995 | 851 | 0.020 |
Why?
| | Vasculitis | 1 | 2011 | 65 | 0.020 |
Why?
| | Vasodilation | 1 | 2013 | 418 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 1014 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1143 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2013 | 2550 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 990 | 0.020 |
Why?
| | Thrombosis | 1 | 2011 | 295 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2018 | 5038 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1131 | 0.020 |
Why?
| | Genes | 1 | 1986 | 223 | 0.020 |
Why?
| | Infant | 1 | 2017 | 7944 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 9049 | 0.010 |
Why?
| | Aged | 1 | 2022 | 18971 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2011 | 1696 | 0.010 |
Why?
| | Child | 1 | 2022 | 18404 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 8614 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1986 | 1310 | 0.010 |
Why?
| | United States | 1 | 2011 | 12137 | 0.010 |
Why?
| | Ditiocarb | 1 | 1994 | 3 | 0.010 |
Why?
| | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1994 | 12 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1994 | 11 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 147 | 0.010 |
Why?
| | Epoprostenol | 1 | 1994 | 133 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1994 | 1003 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1986 | 360 | 0.000 |
Why?
| | Molecular Weight | 1 | 1986 | 328 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1986 | 285 | 0.000 |
Why?
| | Aging | 1 | 1986 | 1612 | 0.000 |
Why?
|
|
Nozik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|